EBITDA Margin % is calculated as EBITDA divided by its Revenue. argenx SE's EBITDA for the
three
months ended in Mar. 2026 was €369 Mil. argenx SE's Revenue for the
three
months ended in Mar. 2026 was €1,123 Mil. Therefore, argenx SE's EBITDA margin for the quarter that ended in Mar. 2026 was 32.90%.
argenx SE (FRA:1AE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
argenx SE EBITDA Margin % Related Terms
argenx SE EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for argenx SE's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1AE vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, argenx SE's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where argenx SE's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (FRA:1AE) has a EBITDA Margin % of 32.90% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #98 out of 944 companies in the Biotechnology industry, placing it in the top 10.4%.
Is argenx SE's EBITDA Margin % too high?
argenx SE's current EBITDA Margin % is 32.90%. Based on the distribution chart, argenx SE ranks #98 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #98 out of 944 companies for EBITDA Margin %. This places argenx SE in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on argenx SE and its competitors. argenx SE's current EBITDA Margin % is 32.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (FRA:1AE) is currently considered Significantly Undervalued. The stock's GF Value™ is €1,163.40, compared to a current price of €753.20 — trading 35.3% below its estimated fair value. The current EBITDA Margin % is 32.90%. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For argenx SE (FRA:1AE), the current EBITDA Margin % is 32.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (FRA:1AE) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of €753.20 is trading 35.3% below its estimated GF Value™ of €1,163.40.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for FRA:1AE:
EBITDA Margin %: 32.90%
GF Value™: €1,163.40 vs. price of €753.20 (35.3% below fair value)
No single metric tells the full story. See the FRA:1AE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score
Get the complete analysis for FRA:1AE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1AE has been successfully added to your 
